Skip to main content

CMMI’s New Enhancing Oncology Model – Deadline Approaching

Doctor working on a tablet.

As the final at-risk period for the Oncology Care Model was closing at the end of June, the Center for Medicare and Medicaid Innovation announced its new Enhancing Oncology Model (EOM). EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. 

What is EOM?

EOM is a voluntary, five-year model set to begin July 1, 2023. Patients undergoing chemotherapy for the treatment of cancer will trigger six-month episodes of care. 

Eligible EOM participants include physician group practices with at least one Medicare-enrolled physician or a non-physician practitioner who furnishes evaluation and management services to Medicare beneficiaries receiving chemotherapy for cancer treatment. 

EOM participants are required to implement eight participant redesign activities to drive care transformation in their practice. Examples include the provision of patient navigation, 24/7 access to an appropriate clinician for beneficiaries and implementation of health-related social needs screenings. 

Quality will be tied to payment in EOM with a combination of participant-reported, claims-based and patient experience survey measures. A limited set of clinical data elements not present in claims data will be collected semiannually. Participating practices will also be required to collect beneficiary-level sociodemographic data and establish a health equity plan to identify and address health disparities. 

Commercial payers, Medicare Advantage plans, and state Medicaid agencies are eligible to apply and partner with CMS for EOM to expand the reach of the model and achieve the goal of delivering high-value, patient-centered cancer care. 

How EOM differs from OCM

EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic leukemia. In OCM, providers were at risk for 21 different cancer types. Patients receiving hormonal therapies only will be excluded from the model. 

The EOM payment methodology will again include monthly enhanced oncology services payments to support care redesign activities; however, these will be paid at a lower rate than under OCM. The MEOS payment will be $70 per beneficiary per month during the six-month episode of care. An additional MEOS payment of $30 will be applied for the management of dual-eligible beneficiaries. 

EOM requires that participating practices take on immediate downside risk from the start of the model. Participants will have two risk arrangements to choose from, which differ in the EOM discount applied (i.e., 3% or 4% of the benchmark), stop-loss and stop-gain thresholds, and whether the arrangement qualifies as an advanced alternative payment model. Both risk arrangements include a neutral zone — a feature introduced late into OCM where an EOM participant does not earn a performance-based payment but also does not meet the threshold for recoupment. 

Despite many characteristics of the EOM target price methodology remaining similar to OCM, several key differences will prove beneficial for participants. The underlying baseline price prediction module now models prices separately for each of the seven cancer types. The impact of comorbidities is modeled with increased specificity, the experience adjustment will take into account practice and regional variability, and the trend factor and novel therapy adjustments have been made cancer-type specific. 

How should practices prepare for the Enhancing Oncology Model?

Physician group practices interested in EOM have until Sept. 30 to submit an application. Even if a practice is currently unsure about participating, applying opens the door for a practice to participate if accepted for the model but does not require the practice to move forward. Practices selected for the model will become participants when they sign their participation agreement. This allows practices to remain in consideration for the model and gives them time to evaluate any additional data that may become available. A participant can terminate participation with no risk, effective immediately, at any point prior to the model’s go-live date.

DataGen has the expertise to help providers conduct baseline evaluations. Contact us to learn more. 

Comments

Popular posts from this blog

One Big Beautiful Bill Act (OBBBA): Hospital reimbursement and Medicare payments [updated]

 Updated on July 9, 2025 The One Big Beautiful Bill Act (OBBBA) — a major budget reconciliation bill passed by the U.S. House of Representatives in May — became law on July 4. While the legislation covers a wide range of national issues, several key Medicare fee-for-service (FFS) provisions could have a direct and lasting impact on hospitals and health systems.  Because OBBBA has Medicare FFS implications, DataGen analyzed the impact of these major areas. Here’s a preview of what we’re seeing so far — and what hospital leaders need to keep on their radar:  update to physician Medicare payments;  potential 4.0% additional Pay-As-You-Go (PAYGO) sequestration reduction; and  Medicare Disproportionate Share Hospital uncompensated care impact.  1. Physician payment updates   For the calendar year 2026, physician payments are slated to increase by 2.5%.   2. The potential new 6% sequester  With the new legislation, Congress may allow the Statutory...

NCQA PCMH 2025 annual reporting: Standards and guidelines

For practices recognized under the National Committee for Quality Assurance’s (NCQA) Patient-Centered Medical Home (PCMH) model, understanding and meeting the NCQA PCMH 2025 annual reporting requirements is critical to sustaining recognition.  NCQA continues to refine its NCQA PCMH standards and guidelines , emphasizing team structure, care continuity and data integrity. Here’s what your practice needs to do to stay compliant and ensure a smooth reporting process. This blog is a continuation of our piece back in July 2024, which listed three updates to NCQA PCMH's 2025 annual reporting requirements . What is NCQA PCMH?  The NCQA Patient-Centered Medical Home (PCMH) is a model of care that emphasizes care coordination, patient engagement and continuous quality improvement. The PCMH framework is designed to improve healthcare outcomes by fostering strong patient-provider relationships and enhancing team-based care.  Since its inception, the NCQA PCMH program has evolved to...